We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cortex Pharmaceuticals has submitted a complete response to each of the points raised by the FDA regarding certain toxicology issues pertaining to its lead Ampakine compound, CX717.
Liponex has initiated patient dosing in its Phase I/II trial of its lead compound CRD5, being developed for the treatment of dyslipidemia and heart disease.
Elite Pharmaceuticals has received approval from an independent review board (IRB) to initiate a Phase II clinical trial of its abuse-resistant pain drug, ELI-216.
Jazz Pharmaceuticals has announced the start of a Phase III trial intended to evaluate the safety and efficacy of Xyrem (sodium oxybate) oral solution as a treatment for fibromyalgia syndrome.
Icagen announced that, following a recent meeting of the independent data monitoring committee (DMC) of the company's Phase III clinical trial for the treatment of sickle cell disease, the DMC recommended that the ASSERT trial continue its enrollment only of patients on concurrent hydroxyurea therapy.